Jake Holdreith, Robins Kaplan Shortlisted For LMG Life Sciences Awards

Robins Kaplan LLP is pleased to announce that Jake Holdreith has been named to LMG Life Sciences 2022 shortlist for Hatch-Waxman Litigator of the Year – Generic. Only six attorneys in the country were recognized on this list. Additionally, the firm was shortlisted for Hatch-Waxman Litigation Firm of the Year – Generic, as well as for Inter-Partes Review Firm of the Year.

Holdreith is a member of the firm’s executive board. He has tried jury cases to multi-million dollar verdicts and resolved complex cases at all stages of litigation. He is a skilled and creative strategist and business counselor who can cut to the heart of a matter in the boardroom and the courtroom. Holdreith counsels clients and tries complex lawsuits in a range of practice areas. He is known for work in in the pharmaceutical, chemical, and electronics industries and has handled cases in the United States, Europe, and Asia.

Holdreith has previously been recognized by LMG Life Sciences as a “Life Sciences Star” and as “General Patent Litigator of the Year.” He was also the recipient of the “Hatch Waxman Impact Cases of the Year” award in 2016.

The firm’s Intellectual Property and Technology Group works across the full spectrum of Hatch-Waxman/ANDA matters, as well as strategic litigation-focused counseling during due diligence and formulation development, and in pharmaceutical-related antitrust matters. The group represents biosimilar, 505(b)(2) and ANDA filers in actions defending patent infringement, asserting patents, before the PTAB and challenging FDA action, in antitrust actions, as well as in business transactions.

You can find a complete list of the nominees here. The winner of this year’s award will be announced at a ceremony in New York City on September 8, 2022.